SYN004

BIOLOGICAL2 trials

Sponsors

Synermore Biologics Co., Ltd.

Conditions

Colon Cancer, Breast Cancer, Cancer of the Head and NeckEpithelial CarcinomaSolid Tumor

Phase 1

Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors

CompletedNCT02391727

Synermore Biologics Co., Ltd.Colon Cancer, Breast Cancer, Cancer of the Head and Neck

Start: 2015-05-31End: 2018-10-31Updated: 2018-11-16

A Study to Find the MTD of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People in Patients With Epithelial Cancers With EGFR Expressions

Synermore Biologics Co., Ltd.Epithelial Carcinoma, Solid Tumor

Start: 2020-04-09End: 2023-09-30Updated: 2023-04-12